Education
About Us
Working with TipRanks
Follow Us
Biotricity (BTCY)
:BTCY
BTCY Stock Chart & Stats
$0.52
-$0.09(-17.87%)
At close: 4:00 PM EST
$0.52
-$0.09(-17.87%)
Day’s Range― - ―
52-Week Range$0.22 - $0.83
Previous CloseN/A
Volume50.15K
Average Volume (3M)53.37K
Market Cap
$15.61M
Enterprise ValueN/A
Total Cash (Recent Filing)$391.29K
Total Debt (Recent Filing)$26.58M
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Nov 12, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding26,567,768
10 Day Avg. Volume88,834
30 Day Avg. Volume53,365
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.53
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Gross MarginGross margin expanded to 80.4% driven by an 84% subscription mix that captures the scale benefits of fixed cloud-hosting and cellular data contracts.
Patent AcquisitionPatent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Product InnovationProduct innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, and strategic partnerships extend Biotricity’s remote monitoring algorithms into new markets.
Bears Say
Neutral RatingWhile there is stable growth and a bullish outlook, a Neutral rating is maintained as expansion consistency, initiative outcomes, and respective financial impact are monitored.
Small-Cap RisksAn investment in Biotricity is subject to the risks inherent in all small-cap companies, including dilution, end-market product acceptance and pricing, and competition against companies with greater resources.
Biotricity News
BTCY FAQ
What was Biotricity’s price range in the past 12 months?
Biotricity lowest stock price was $0.22 and its highest was $0.83 in the past 12 months.
What is Biotricity’s market cap?
Biotricity’s market cap is $15.61M.
When is Biotricity’s upcoming earnings report date?
Biotricity’s upcoming earnings report date is Nov 12, 2025 which is in 15 days.
How were Biotricity’s earnings last quarter?
Biotricity released its earnings results on Aug 14, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of N/A by $0.03.
Is Biotricity overvalued?
According to Wall Street analysts Biotricity’s price is currently Overvalued.
Does Biotricity pay dividends?
Biotricity does not currently pay dividends.
What is Biotricity’s EPS estimate?
Biotricity’s EPS estimate is -0.08.
How many shares outstanding does Biotricity have?
Biotricity has 26,567,768 shares outstanding.
What happened to Biotricity’s price movement after its last earnings report?
Biotricity reported an EPS of $0.03 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biotricity?
Currently, no hedge funds are holding shares in BTCY
Company Description
Biotricity
Biotricity Inc. (BTCY) is a medical technology company that specializes in the development and commercialization of remote biometric monitoring solutions. The company focuses on delivering innovative, real-time remote monitoring solutions for chronic conditions and lifestyle improvement. Its core product, Bioflux, is a mobile cardiac telemetry device that provides continuous, real-time monitoring for patients with cardiac conditions, enhancing the capabilities of healthcare providers to diagnose and manage these conditions effectively.
BTCY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biotricity showed significant advancements and strategic partnerships leading to revenue growth and reduced operating expenses, positioning the company close to profitability. Despite ongoing net losses and long sales cycles, the positive developments, such as international approvals and gross margin improvements, indicate a strong trajectory towards sustainable growth.View all BTCY earnings summariesTechnical Analysis
Vivos Therapeutics
―
Adagio Medical Holdings
―
Inspira Technologies Oxy BHN
―
Tivic Health Systems
―
Heart Test Laboratories, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.18% Other Institutional Investors
99.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---